Boule Diagnostics AB (CHIX:BOULS) Cyclically Adjusted FCF per Share: kr-2.20 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BOULS Boule Diagnostics AB CHIX:BOULS
47 GF Score
Price kr26.30
GF Value kr49.42
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Cyclically Adjusted FCF per Share?

Boule Diagnostics AB CHIX:BOULS 47 Cyclically Adjusted FCF per Share is kr-2.20 as of Mar. 2026. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Boule Diagnostics AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr0.270. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-2.20 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -45.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Boule Diagnostics AB was -45.70% per year. The lowest was -54.20% per year. And the median was -49.95% per year.

As of today (2026-07-14), Boule Diagnostics AB's current stock price is kr26.30. Boule Diagnostics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-2.20. Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Boule Diagnostics AB was 4907.19. The lowest was 361.53. And the median was 1106.42.


Boule Diagnostics AB  (CHIX:BOULs) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Boule Diagnostics AB was 4907.19. The lowest was 361.53. And the median was 1106.42.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Boule Diagnostics AB Cyclically Adjusted FCF per Share Related Terms


Boule Diagnostics AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Cyclically Adjusted FCF per Share Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 -0.19 -0.26 -0.76 -1.82

Boule Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.75 -0.75 -1.52 -1.82 -2.20

CHIX:BOULS vs ABT, SYK, MDT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boule Diagnostics AB Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF falls into.


CHIX:BOULS
47GF Score
Boule Diagnostics AB CHIX:BOULS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boule Diagnostics AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Boule Diagnostics AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.27/133.5600*133.5600
=0.270

Current CPI (Mar. 2026) = 133.5600.

Boule Diagnostics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.086 101.019 -0.114
201609 0.457 101.138 0.604
201612 0.348 102.022 0.456
201703 0.645 102.022 0.844
201706 0.073 102.752 0.095
201709 0.264 103.279 0.341
201712 0.592 103.793 0.762
201803 0.000 103.962 0.000
201806 -0.747 104.875 -0.951
201809 -0.354 105.679 -0.447
201812 -0.428 105.912 -0.540
201903 -0.652 105.886 -0.822
201906 0.095 106.742 0.119
201909 0.497 107.214 0.619
201912 0.289 107.766 0.358
202003 0.087 106.563 0.109
202006 0.200 107.498 0.248
202009 0.351 107.635 0.436
202012 0.379 108.296 0.467
202103 -0.090 108.360 -0.111
202106 -0.198 108.928 -0.243
202109 -0.050 110.338 -0.061
202112 -0.169 112.486 -0.201
202203 -0.758 114.825 -0.882
202206 -1.014 118.384 -1.144
202209 -1.215 122.296 -1.327
202212 -0.121 126.365 -0.128
202303 -0.643 127.042 -0.676
202306 -0.507 129.407 -0.523
202309 0.133 130.224 0.136
202312 0.204 131.912 0.207
202403 -0.227 132.205 -0.229
202406 -0.288 132.716 -0.290
202409 -0.291 132.304 -0.294
202412 -0.199 132.987 -0.200
202503 -0.225 132.825 -0.226
202506 -0.076 133.699 -0.076
202509 -0.013 133.480 -0.013
202512 0.198 133.390 0.198
202603 0.270 133.560 0.270

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-2.20 mean?
Boule Diagnostics AB (CHIX:BOULS) has a Cyclically Adjusted FCF per Share of kr-2.20 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Cyclically Adjusted FCF per Share too high?
Boule Diagnostics AB's current Cyclically Adjusted FCF per Share is kr-2.20. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Cyclically Adjusted FCF per Share compare to ABT and SYK?
Boule Diagnostics AB's Cyclically Adjusted FCF per Share of kr-2.20 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Cyclically Adjusted FCF per Share is kr-2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Cyclically Adjusted FCF per Share of kr-2.20. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-2.20. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Cyclically Adjusted FCF per Share is kr-2.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.

Key valuation signals for CHIX:BOULS:

  • Cyclically Adjusted FCF per Share: kr-2.20
  • GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for CHIX:BOULS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.30
Price
kr49.42
GF Value